Vanguard Group’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.96M | Buy |
847,751
+21,138
| +3% | +$48.8K | ﹤0.01% | 3538 |
|
|
2025
Q1 | $6.46M | Buy |
826,613
+88,412
| +12% | +$690K | ﹤0.01% | 3072 |
|
|
2024
Q4 | $3.45M | Buy |
738,201
+17,489
| +2% | +$81.7K | ﹤0.01% | 3401 |
|
|
2024
Q3 | $3.88M | Buy |
720,712
+92,413
| +15% | +$498K | ﹤0.01% | 3365 |
|
|
2024
Q2 | $5.54M | Buy |
628,299
+86,970
| +16% | +$767K | ﹤0.01% | 3215 |
|
|
2024
Q1 | $6.36M | Hold |
541,329
| – | – | ﹤0.01% | 3196 |
|
|
2023
Q4 | $6.1M | Sell |
541,329
-9,251
| -2% | -$104K | ﹤0.01% | 3202 |
|
|
2023
Q3 | $3.73M | Hold |
550,580
| – | – | ﹤0.01% | 3369 |
|
|
2023
Q2 | $5M | Buy |
550,580
+8,937
| +2% | +$81.1K | ﹤0.01% | 3304 |
|
|
2023
Q1 | $3.5M | Hold |
541,643
| – | – | ﹤0.01% | 3468 |
|
|
2022
Q4 | $3.43M | Buy |
541,643
+245
| +0% | +$1.55K | ﹤0.01% | 3464 |
|
|
2022
Q3 | $3.36M | Sell |
541,398
-12,240
| -2% | -$75.9K | ﹤0.01% | 3523 |
|
|
2022
Q2 | $4.89M | Hold |
553,638
| – | – | ﹤0.01% | 3385 |
|
|
2022
Q1 | $4.66M | Buy |
553,638
+42,609
| +8% | +$359K | ﹤0.01% | 3569 |
|
|
2021
Q4 | $5.21M | Buy |
511,029
+62,118
| +14% | +$634K | ﹤0.01% | 3587 |
|
|
2021
Q3 | $8.72M | Buy |
448,911
+69,743
| +18% | +$1.35M | ﹤0.01% | 3325 |
|
|
2021
Q2 | $6.66M | Buy |
379,168
+65,948
| +21% | +$1.16M | ﹤0.01% | 3425 |
|
|
2021
Q1 | $3.72M | Buy |
313,220
+60,289
| +24% | +$716K | ﹤0.01% | 3673 |
|
|
2020
Q4 | $4.36M | Buy |
252,931
+46,236
| +22% | +$796K | ﹤0.01% | 3424 |
|
|
2020
Q3 | $2.13M | Buy |
+206,695
| New | +$2.13M | ﹤0.01% | 3469 |
|